



BOARD CHANGES

21 November 2017, Melbourne: The Executive Chairman of IDT, Mr Graeme Kaufman, has advised that he is standing down from the position of Chairman with effect from today. Mr Kaufman will continue as a Director and will continue in his interim executive role.

The Board has appointed Mr Alan Fisher as Chairman. Mr Fisher has extensive business and corporate experience and in particular has expertise in financial and operational restructuring. He has been a Director of IDT since 2015.

As a consequence of Mr Fisher's appointment, his role as Chair of the Audit and Risk Committee will be assumed by Mr Hugh Burrill and Ms Mary Sontrop will take over the role of Chair of the Remuneration and Nominations Committee.

ENDS

For further information please contact:
IDT Australia Limited
Graeme Kaufman
Executive Director
0409 013 063

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of finished drug dose forms.